The role of lopinavir/ritonavir (Kaletra®) in the management of HIV infected adults

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 3, 2003, Pages 389-401

  Walmsley, Sharon ^a   Christian, Michael D ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HIV Clinical and Research   (Canada)

Author keywords

ARV; HIV; Lopinavir; PI; Resistance; Salvage therapy

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ATAZANAVIR; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PHENYTOIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE; ZIRET;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; LIVER DYSFUNCTION; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; NAUSEA; PATIENT CARE; REVIEW; STRUCTURE ANALYSIS; VOMITING;

EID: 3042701073     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.3.389     Document Type: Review

References (62)

1. Sepkowitz KA. AIDS: the first 20 years. N. Engl. J. Med. 344(23), 1764-1772 (2001).
2. Yeni SG, Hammer SM, Carpenter CCJ et al. Antiretroviral treatment for adult HIV infection in 2002. JAMA 288(2), 222-235 (2002).
3. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 137(5), 381-433 (2002).
4. DeJesus E. The Context Study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). 10th Conf. Retroviruses Opp. Infect. (2003) (Abstract no. 178).
5. Gathe et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI1182.52. 10th Conf. Retroviruses Opp. Infect. (2003) (Abstract no. 179).
6. Piscitelli S, Bechtel C, Sadler B, Falloon J. Addition of a second protease inhibitor eliminates amprenavir-efavirenz interactions and increased amprenavir concentrations. 7th Conf. Retroviruses Opp. Infect. (2000) (Abstract no. 78).
7. Kilby M, Hill AM, Buss N. Effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of 120 subjects. 40th Interscience Conf. Antimicrob. Agents Chemother. (2000) (Abstract no. 1650).
8. Saah AJ, Winchell G, Seniuk M, Deutsch P. Multiple-dose pharmacokinetics and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers. 6th Conf. Retroviruses Opp. Infect. (1999) (Abstract no. 362).
9. Haas D, Zala C, Schrader S et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 17, 1339-1349 (2003).
10. Sham HL, Kempf DJ, Molla A et al. ABT-378, a highly potent inhibitor of the human immunodeficiency vinis protease. Antimicrob. Agents Chemother. 42(12), 3218-3224 (1998).
11. Bertz R, Renz C, Foit C et al. Steady-state pharmacokinetics of Kaletra in HIV-infected subjects when taken with food. Proc. Sec. Internat. Workshop Clin. Pharmacol. HIV Ther. Noordwijk, The Netherlands 3, 1 (2001) (Abstract).
12. Abramowicz M. Lopinavir/ritonavir: a protease-inhibitor combination. Med. Lett. 43 (1095), 1-2 (2001).
13. Issac A, Taylor S, Rubin G et al. Lopinavir/ritonavir combined with twice-daily indinavir: Pharmacikinetics in blood, CSF, and semen (The Protect Study). 10th Conf. Retroviruses Opp. Infect. (2003) (Poster no. 531).
14. Bertz R, Foit C, Ashbrenner E et al. Effect of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in HIV+ and healthy subjects. 42th Interscience Conf. Antimicrob. Agents Chemother. (2002) (Poster no. A-1823).
15. la Porte CJL, Colbers EPH, Bertz R, Koopmans PP, Kekster YA, Burger DM. Pharmacokinetics of two adjusted dose regimens of lopinavir/ritonavir in combination with rifampin in healthy volunteers. 42th Interscience Conf. Antimicrob. Agents Chemother. (2002) (Poster no. A-1821).
16. Lim ML, Min SS, Eron JJ et al. A two-way drug interaction between lopinavir/ritonavir and phenytoin. 10th Conf. Retroviruses Opp. Infect. (2003) (Poster no. 535).
17. Clarke S, Mulcahy F, Bergin C et al. Absence of opiod withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin. Infect. Dis. 34, 1143-1145 (2002).
18. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann. Pharmacother. 36, 598-613 (2002).
19. Murphy R, Brun S, King M et al. Lopinavir/ritonavir in antiretroviral-naive HIV+ patients: 4-year follow-up. 42nd Interscience Conf. Antimicrob. Agents Chemother. (2002) (Poster no. H-165).
20. King M, Perrin L, Yerly S, Real K, Tokimoto D, Brun S. Failure to achieve HIV RNA # 3 copies/ml by week 72 is not associated with loose of virologic response through 4 years of lopinavir/ritonavir-based therapy. 6th Intern. Congress Drug Ther. (2002).
21. Kessler H, Heath-Chiozzi M, King M et al. CD4 cell increases through more than 4 years in anti-retroviral-naive HIV+ patients treated with lopinavir/ritonavir-based therapy. 2nd IAS (Abstract no. 568).
22. Thompson M, Brun S, Xu Y et al. Analysis of duration of virologic response in two phase II studies of ABT-378/ritonavir at 72 weeks. XIII Intern. AIDS Conf. (2000) (Abstract no. TuPeB3197).
23. Tebas P, Patick AK, Kane EM et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 13(2), F23-28 (1999).
24. Zolopa AP, Shafer RW, Watford A et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131 (11), 813-821 (1999).
25. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346(26), 2039-2046 (2002).
26. Kempf D, King M, Bauer E et al. Comparative incidence and temporal accumulation of PI and NRTI Resistance in HIV-infected subjects receiving Kaletra or Nelfinavir as initial therapy. 10th Conf. Retroviruses Opp. Infect. (2003).
27. King M, Bernstein B, Cernohous P, Moseley J, Bauer K, Sun E. Impact of baseline CD4 cell count and viral load on durability of virologic response through 96 weeks for lopinavir/ritonavir and nelfinavir in a Phase III clinical trial. 9th Conf. Retroviruses Opp. Infect. (2002) (Poster no. 470-M).
28. Cernohous P, Bernstein B, Mosley et al. Safety and efficacy of lopinavir/ritonavir in women in a Phase III study of antiviral-naïve subjects. 14th World AIDS Conf. Barcelona, Spain (2002) (Poster no. B5972).
29. King M, Brun S, Tschampa J et al. Relationship between adherence and the development of viral resistance in antiretroviral-naïve patients treated with lopinavir/ritonavir or nelfinavir. 2nd IAS (2003) (Poster no. 798).
30. Kempf D, Isaacson J, King M et al. Genotypic correlates of reduced in vitro susceptibility to ABT-378 in HIV isolates from patients failing protease inhibitor therapy. 4th Internat. Workshop HIV Drug Resist. Treat. Strategies (2000) (Abstract 38).
31. Hsu A, Kemph K, Granneman R, Sun E. Exploring theoretical mechanisms for lack of resistance to lopinavir/ritonavir in antiretroviral-naive subjects. 9th Conf. Retroviruses Opp. Infect. (2002) (Poster no. 436-W).
32. Molla A, Brun S, Mo H et al. Genotypic and phenotypic analysis of viral isolates from subjects with detectable viral load on therapy with ABT-378/ritonavir. 4th Internat. Workshop HIV Drug Resist. Treat. Strategies (2000) (Abstract 39).
33. Kempf D, Isaacson J, King M et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antiviral Ther. 7(3), 165-74 (2002).
34. Isaacson J, Kempf D, Calvez V et al. Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. 9th Conf. Retroviruses Opp. Infect. (2002) (Poster no. 559-T).
35. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17, 955-961 (2003).
36. Squires K, McCallister S, Lizzarin A et al. Tipranavir/ritonavir demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: correlation of baseline genotype and antiviral activity in BI 1182.52. 2nd IAS (Abstract no. 812).
37. Reitmayer R, Rode F, Bernstein B et al. Results from the KaletraTM early access program. 2001 Interscience Conf. Antimicrob. Agents Chemother. (Poster no. 328).
38. Bernstein B, King M, Brun S et al. Safety of Kaletra™: data from Phase II and Phase III clinical trials. 1st IAS Conf. HIV Pathogenesis Treat. (2001).
39. Badaro R, DeJesus E, Lassarin A et al. Efficacy and safety of atazanavir with ritonavir or saquinavir versus lopinavir/ritonavir in combination with tenofovir and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16 week results from BMS AI424-045. 2nd IAS (Abstract no. 118).
40. Lee GA, Senevirate T, Noor MA et al. Metabolic effects of lopinavir/ritonavir in healthy HIV-seronegative men. 10th Conf. Retroviruses Opp. Infect. (2003) (Poster no. 748).
41. Calboreanu. A, Dimet J, Treluyer M et al. Relation between lopinavir plasma blood concentration and hypertriglyceridemia in naï ve and protease inhibitors-experienced patients. 10th Conf. Retroviruses Opp. Infect. (2003) (Poster no. 526).
42. Sulkowski MS; Thomas DL; Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283, 74-80 (2000).
43. Wit FWMN, Weverling GJ, Weel J et al. incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J. Infect. Dis. 186, 23-31 (2002).
44. Bernstein B, King M, Cernohous P, Moseley J, Sun E. Treatment of HIV+ subjects coinfected with Hepatitis B or C: week 60 safety and efficacy comparison of LPV/r vs Nelfinavir from a Phase III blinded randomized clinical trial. 8th ECCATHI, Athens, Greece (2002) (Poster no. 228).
45. Andrade-Neto JL, Soto A, Sprinz E et al. Improved tolerability and quality of life in subjects receiving lopinavir/ritonavir. 6th Internat Congress Drug Ther. in HIV Infection (2002) (Poster no. P9).
46. Hayden R, Rode R, Mingrone H et al. Evaluation of side effect tolerability and quality of life measures in patients after substitution of their PI/NNRTI with lopinavir/ritonavir. 2nd IAS (Abstract no. 557).
47. Matetzky S, Domingo M, Kar S et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch. Intern. Med. 163(4), 457-60 (2003)
48. Friis-Møller N, Weber R, D'Arminio Monforte A. Exposure to HAART is associated with an increased risk of myocardial infarction: the D:A:D study. 10th Conf. Retroviruses Opp. Infect. BA, USA (2003) (Abstract no. 130).
49. Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348, 702-710 (2003).
50. Ferre V, Allavena C, Poizot-Martin I et al. BIKS study (lopinavir/ritonavir-efavirence combination): complete 24-week results. 2nd IAS (Abstract no. 36).
51. Raffi F, Saag M, Cahn P et al. A randomized double-blind, multicenter comparison of emtricitabine QD to stavudine BID in treatment-naive HIV-infected patients. 2nd IAS (Abstract no. 38).
52. Fichtenbaum CJ, Gerber JG, Rosenkranz SL. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569-577 (2002).
53. Gil P, Gorgolas M, Estrada V et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV patients with undetectable viral load. 2nd IAS (Abstract no. 590).
54. Moya J, Casado S, Diz A et al. Efficacy and safety of a once daily regimen with NNRTIs after a successful protease inhibitor-containing regimen. 2nd IAS (Abstract no. 591).
55. Weiss L, Aboulhab J, Babiker GA et al. Preliminary results of ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomised International Trial): Baseline predictors of CD4 T-cell response to interteukin-2. 2nd IAS (Abstract no. 13).
56. Chan P, Dragsted UB, Pedersen C et al. Maxcmin 1 compared SQV/r withIDV/r and found that SQV/r was better tolerated the IDV/r but was equally efficacious. Maxcmin 2 is currently underway evaluating SQV/r vs LPV/r. XIV Internat. AIDS Conf. (2002) (Poster no. WeOrB1265).
57. Youle M, Gerstoft J, Fox Z et al. The final week 48 analysis of a phase IV randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg; BID) versus Saquinavir/ritonavir (1000/100 mg BID) in adult HIV-1 infection: the MaxCmin2 trial. 2nd IAS, Paris, France (2003) (Abstract LB23).
58. Nieto-Cisneros L, Zala C, Fessel WJ et al. Antiviral efficacy, metabolic changes and safety of atazanavir versus lopinavir/ritonavir in combination with 2 NRTIs in patients who have experienced virologic failure with prior PI-containing regimen(s): 24-week results from BMS AI424-043. 2nd IAS (Abstract no. 117).
59. DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). 10th Conf. Retroviruses Opp. Infect. (2003) (Abstract 178).
60. Elston R, MacManus S, Yates P et al. Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naïve subjects. 2nd IAS (Abstract no. 558).
61. Staszewski S, Dauer B, Von Hentig N et al. The LOPSAQ study: 24 week analysis of the double protease inhibitor salvage regimen containing lopinavir/ritonavir plus saquinavir without any additional antiretroviral therapy. 2nd IAS Paris, France (2003) (Abstract no. 583).
62. Raguin G, Chene G, Morand-Joubert L et al. Salvage therapy with lopinavir/ritonavir, amprenavir +/- an additional boost with ritonavir: 1-year results of puzzle 1-ANRS 104 study. 2nd IAS Paris, France (2003) (Abstract no. 585).